Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...

Luqa Pharma Out-licenses AfMET Rights for AntiFungal; Keeps China Rights

publication date: Apr 18, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Luqa Pharma, a drug company based in Hong Kong, out-licensed the rights for Ebernet®, a topical antifungal product, to NewBridge Pharmaceuticals for countries in Africa, the Middle East, Turkey and the Caspian Regions (AfMET). Luqa retains the rights to the drug in China and the greater Asia-Pacific region. Luqa acquired Asian and AfMET rights to Ebernet in a 2010 agreement with SALVAT Labs, the Spanish drug company that originally developed the product. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Partnering Forum 2013
  May 29-30, 2013
Beijing, China

>>More events...
Partner Events

China Medical Affairs Summit
  June 18-19, 2013
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners